Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03739710 · ClinicalTrials.gov registry record · Phase 2
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
NCT03739710 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 175 participants.
The verdict
NCT03739710, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
Study Summary
This study will compare the clinical activity of novel regimens (in combination or as single agents) to SoC in participants with relapsed/refractory advanced NSCLC. The study will be conducted in two parts. Part 1 is an open-label, optional, non-randomized part based on safety and pharmacokinetics/pharmacodynamics (PK/PD) evaluation intended to generate additional data to qualify novel regimens for the randomized study. Part 2 is a randomized, Phase II open-label part comparing the efficacy and safety of these novel regimens with SoC. Drug name mentioned as GSK4428859A (belrestotug) and EOS884448 are interchangeable for the same compound and will be referred to as GSK4428859A/EOS884448/belrestotug.
Interventions
- DRUG Docetaxel
- DRUG Ipilimumab
- DRUG Dostarlimab
- DRUG Feladilimab
- DRUG GSK4428859A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2019-01-24 |
| Est. Completion | 2024-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03739710
The ClinicalTrials.gov registry entry for NCT03739710 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT03739710 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03739710 about?
NCT03739710 is a clinical study titled "Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)". This study will compare the clinical activity of novel regimens (in combination or as single agents) to SoC in participants with relapsed/refractory advanced NSCLC. The study will be conducted in two parts. Part 1 is an open-label, optional, non-randomized part based on safety and pharmacokinetics/p...
What is the current status of trial NCT03739710?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2019-01-24. Estimated completion is 2024-05-02.
What interventions are being tested in trial NCT03739710?
The interventions under investigation include: Docetaxel (DRUG), Ipilimumab (DRUG), Dostarlimab (DRUG), Feladilimab (DRUG), GSK4428859A (DRUG).
Who is sponsoring clinical trial NCT03739710?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.